# US 2021/0332385 A1 · Gene therapies for lysosomal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332385 A1
- Document ID: US20210332385A1
- Status: Published application
- Kind: A1
- Application number: 17/369,168
- Filed: 2021-07-07
- Published: 2021-10-28
- Earliest claimed: 2017-10-03
- Assignees: Prevail Therapeutics, Inc.
- Applicants: Prevail Therapeutics, Inc.
- Inventors: Asa ABELIOVICH; Laura HECKMAN; Herve RHINN
- Web page: https://patentgrep.com/patent/US20210332385A1

## CPC

- C12N 15/861: Adenoviral vectors
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 14/435: from animals; from humans
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- C12Y 302/01045: Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2710/14043: viral genome or elements thereof as genetic vectore
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.

## Claims

### Claim at position 1

-43. (canceled)

### Claim 44

An isolated nucleic acid comprising:
(i) an expression construct comprising a promoter operably linked to a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15, which is a codon optimized version of wild type GBA1 nucleotide sequence, wherein the codon optimized sequence eliminates a predicted donor splice site that begins at nucleotide 49 in the wild type GBA1 nucleotide sequence; and
(ii) two adeno-associated virus (AAV) inverted terminal repeat (ITR) sequences flanking the expression construct.

### Claim 45 (depends on 44)

The isolated nucleic acid of claim 44, wherein the promoter is a chicken beta actin (CBA) promoter.

### Claim 46 (depends on 44)

The isolated nucleic acid of claim 44, further comprising a CMV enhancer.

### Claim 47 (depends on 44)

The isolated nucleic acid of claim 44, further comprising a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE).

### Claim 48 (depends on 44)

The isolated nucleic acid of claim 44, further comprising a Bovine Growth Hormone polyA signal tail.

### Claim 49 (depends on 44)

The isolated nucleic acid of claim 44, wherein each ITR sequence is a wild-type AAV2 ITR sequence.

### Claim 50 (depends on 44)

The isolated nucleic acid of claim 44, wherein each ITR sequence comprises a “D” region (SEQ ID NO: 27) that is proximal to the expression construct.

### Claim 51 (depends on 44)

The isolated nucleic acid of claim 44, wherein at least one of the ITR sequences comprises a “D” region (SEQ ID NO: 27) positioned on the outside of the ITR sequence relative to the expression construct.

### Claim 52 (depends on 44)

The isolated nucleic acid of claim 44, wherein the ITR sequence positioned 5′ relative to the expression construct comprises a “D” region (SEQ ID NO: 27) that is proximal to the expression construct, and the ITR sequence positioned 3′ relative to the expression construct comprises a “D” region (SEQ ID NO: 27) positioned on the outside of the ITR sequence relative to the expression construct.

### Claim 53 (depends on 52)

The isolated nucleic acid of claim 52, wherein the nucleic acid sequence of the 5′ ITR is nucleotides 1-145 of SEQ ID NO: 1 and the nucleic acid sequence of the 3′ ITR is nucleotides 3867-4011 of SEQ ID NO: 1.

### Claim 54 (depends on 52)

The isolated nucleic acid of claim 52, further comprising a TRY region between the 5′ ITR and the expression construct, wherein the TRY region has the sequence set forth in SEQ ID NO: 28.

### Claim 55

An isolated nucleic acid comprising, in 5′ to 3′ order:
(a) a 5′ AAV ITR;
(b) a CMV enhancer;
(c) a CBA promoter;
(d) a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15;
(e) a WPRE;
(f) a Bovine Growth Hormone polyA signal tail; and
(g) a 3′ AAV ITR.

### Claim 56

A plasmid comprising a nucleic acid comprising:
(i) an expression construct comprising a promoter operably linked to a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15, which is a codon optimized version of wild type GBA1 nucleotide sequence, wherein the codon optimized sequence eliminates a predicted donor splice site that begins at nucleotide 49 in the wild type GBA1 nucleotide sequence; and
(ii) two AAV ITR sequences flanking the expression construct.

### Claim 57

A Baculovirus vector comprising a nucleic acid comprising:
(i) an expression construct comprising a promoter operably linked to a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15, which is a codon optimized version of wild type GBA1 nucleotide sequence, wherein the codon optimized sequence eliminates a predicted donor splice site that begins at nucleotide 49 in the wild type GBA1 nucleotide sequence; and
(ii) two AAV ITR sequences flanking the expression construct.

### Claim 58

A cell comprising:
(i) a first vector encoding one or more adeno-associated virus rep proteins and/or one or more adeno-associated virus cap proteins; and
(ii) a second vector comprising a nucleic acid comprising:
(a) an expression construct comprising a promoter operably linked to a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15, which is a codon optimized version of wild type GBA1 nucleotide sequence, wherein the codon optimized sequence eliminates a predicted donor splice site that begins at nucleotide 49 in the wild type GBA1 nucleotide sequence; and
(b) two AAV ITR sequences flanking the expression construct.

### Claim 59 (depends on 58)

The cell of claim 58, wherein
(i) the first vector is a plasmid and the second vector is a plasmid; or
(ii) the first vector is a Baculovirus vector and the second vector is a Baculovirus vector.

### Claim 60 (depends on 58)

The cell of claim 58, wherein the cell is a mammalian cell or an insect cell.

### Claim 61 (depends on 60)

The cell of claim 60, wherein the mammalian cell is a HEK293 cell.

### Claim 62 (depends on 58)

A method of producing a recombinant adeno-associated virus (rAAV), the method comprising:
(i) culturing the cell of claim 58 under conditions allowing for packaging the rAAV; and
(ii) harvesting the cultured host cell or culture medium for collection of the rAAV.

### Claim 63 (depends on 62)

The method of claim 62, wherein the rAAV comprises an AAV9 capsid protein.

### Claim 64

A method for treating Gaucher disease in a subject, the method comprising administering to the subject a rAAV comprising:
(i) an AAV9 capsid protein; and
(ii) a rAAV vector comprising a nucleic acid comprising an expression construct comprising a promoter operably linked to a transgene insert encoding a Gcase protein, wherein the transgene insert comprises the nucleotide sequence of SEQ ID NO: 15, which is a codon optimized version of the wild type GBA1 nucleotide sequence, wherein the codon optimized sequence eliminates a predicted donor splice site that begins at nucleotide 49 in the wild type GBA1 nucleotide sequence, and wherein the rAAV vector comprises two adeno-associated virus inverted terminal repeats (ITR) sequences flanking the expression construct;
thereby mediating the treatment of the Gaucher disease in the subject.

### Claim 65 (depends on 64)

The method of claim 64, wherein the administration comprises direct administration to the central nervous system (CNS) of the subject.

### Claim 66 (depends on 65)

The method of claim 65, wherein the direct administration to the CNS is intra-cisterna magna injection, intracerebral injection, intraparenchymal injection, intrathecal injection, or any combination thereof.

### Claim 67 (depends on 64)

The method of claim 64, wherein the administration comprises peripheral administration.

### Claim 68 (depends on 67)

The method of claim 67, wherein the peripheral administration is intravenous administration.

### Claim 69 (depends on 64)

The method of claim 64, wherein the Gaucher disease is type 1 Gaucher disease, type 2 Gaucher disease or type 3 Gaucher disease.
